Home LiteratureArticle Details
PMID: 12771621 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Therapeutic potential for transient inhibition of adenosine deaminase in systemic inflammatory response syndrome.

Critical care medicine ·Vol. 31 ·No. 5 ·2003-05-00 ·Pages 1475-81

Law WR, Valli VE, Conlon BA

Abstract

We sought to determine the potential usefulness of 2'-deoxycoformycin (pentostatin), an inhibitor of adenosine deaminase, as a postinsult, or prophylactic treatment for systemic inflammatory response syndrome resulting from fecal peritonitis. Prospective, randomized, controlled experiment. Small animal basic science laboratory. Male Spague-Dawley rats, weighing 300 to 350 g. Rats with fecal peritonitis (intraperitoneal cecal slurry) were treated with 1 mg/kg pentostatin intraperitoneally 24 hrs before, or intravenously when signs of illness presented (2 hrs after induction of peritonitis). Signs of illness included tachycardia, tachypnea, and leukopenia. All rats received 50 mL/kg 0.9% saline resuscitative fluid at 2 hrs. Survival to day 6 was 100% in nonseptic sham rats, but 33% in untreated septic rats. In rats given pentostatin either 2 hrs after the insult, or 24 hrs before the insult, 6-day survival improved to 81% and 78%, respectively. Histology revealed diffuse peritonitis, and evidence of systemic inflammatory response syndrome, including local and distant site vascular damage and leukocyte activation. These responses to the septic challenge were abrogated by pentostatin treatment. Return of significant amount of tissue adenosine deaminase activity by 24 hrs and later recovery of white blood cell counts argue against any potential for inappropriate immunosuppression by pentostatin. These data indicate that the novel use of pentostatin to prevent systemic inflammatory response syndrome secondary to fecal peritonitis shows uncommon promise as a therapeutic tool. All indices of systemic inflammatory response syndrome were abrogated and survival improved when pentostatin was not given until after signs of the illness became manifest. Because protection was afforded with treatment 24 hrs in advance of the inciting insult, pentostatin also has the unique potential for use as a true prophylactic agent.

MeSH Terms
Adenosine Deaminase/analysis,immunology Adenosine Deaminase Inhibitors Animals Disease Models, Animal Drug Evaluation, Preclinical Feces Immunosuppressive Agents/pharmacology,therapeutic use Infusions, Intravenous Injections, Intraperitoneal Leukocyte Count Male Pentostatin/pharmacology,therapeutic use Peritonitis/complications Proportional Hazards Models Prospective Studies Random Allocation Rats Rats, Sprague-Dawley Survival Analysis Systemic Inflammatory Response Syndrome/drug therapy,enzymology,microbiology,mortality,prevention & control Time Factors
Chemicals
Adenosine Deaminase Inhibitors Immunosuppressive Agents Pentostatin Adenosine Deaminase
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Law William R
University of Illinois, College of Medicine at Chicago, 60612, USA. [email protected]
Valli Victor E
Conlon Beth A
Article Info
Journal
Critical care medicine
Abbr.
Crit Care Med
ISSN
0090-3493
Published
2003-05-00
Pages
1475-81
Language
English
Region
United States
NLM ID
0355501
Subset
IM
Grants
NIGMS NIH HHS · R41 GM065593 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]